Janssen v. Macleods: INVOKAMET® Patent Dispute Resolved by Consent Judgment in 208 Days
Janssen Pharmaceuticals and Janssen Pharmaceutica N.V. filed suit against Macleods Pharmaceuticals in New Jersey District Court over US11576894B2, a patent covering INVOKAMET® canagliflozin/metformin hydrochloride combination tablets. The parties resolved the dispute through a consent judgment — signed by Judge Georgette Castner on October 29, 2024 — just 208 days after filing.
ANDA Infringement Dispute Over Canagliflozin/Metformin Combination Resolved by Agreement
On April 4, 2024, Janssen Pharmaceuticals, Inc. and its affiliate Janssen Pharmaceutica N.V. filed a patent infringement action in the District of New Jersey against Macleods Pharmaceuticals and its U.S. subsidiary Macleods Pharma USA, Inc. The complaint asserted US11576894B2, a patent covering INVOKAMET® — Janssen’s branded canagliflozin and metformin hydrochloride combination tablets indicated for type 2 diabetes — in strengths of 50 mg/500 mg, 50 mg/1000 mg, 150 mg/500 mg, and 150 mg/1000 mg. The suit is consistent with standard Hatch-Waxman ANDA litigation, where a branded pharmaceutical company challenges a generic applicant’s proposed entry.
The case closed on October 29, 2024, when Judge Georgette Castner signed a Consent Judgment and Order. A consent judgment is a negotiated resolution that takes the form of a court order, giving it enforcement authority — meaning neither party can unilaterally reopen the merits. Crucially, the court expressly retained jurisdiction over both Janssen and Macleods for enforcement purposes, indicating the order contains substantive obligations binding both sides. The specific terms — including any agreed market entry date for Macleods — are not detailed in the publicly available record.
Resolution in 208 days is notably swift for pharmaceutical patent litigation in New Jersey, one of the busiest ANDA dockets in the country, and is consistent with early settlement or a negotiated licence with delayed entry provisions. The speed suggests Macleods may have accepted entry restrictions in exchange for a defined future launch date, though the public record does not confirm this. What drove the agreement — relative patent strength, trial risk, or commercial negotiation — remains undisclosed.
Filing to Consent Judgment in 208 days
208 days — faster than median ANDA patent litigation in D.N.J., suggesting early negotiated resolution
Consent judgment entered: what the court order means for Janssen and Macleods
A consent judgment is a court order, not just a settlement agreement
Unlike a private settlement agreement, a consent judgment is entered by the court and carries the full enforcement weight of a judicial order. Judge Castner’s order expressly reserves jurisdiction over both Janssen and Macleods, meaning either party can return to court to compel compliance without initiating new litigation. This structure is common in Hatch-Waxman cases where branded manufacturers agree to permitted launch dates and generic applicants agree to entry restrictions.
Court-enforceable agreed orderJanssen secures enforceable protection over INVOKAMET® patent rights
A consent judgment in the patent holder’s favour — or one containing entry restrictions — effectively preserves exclusivity for US11576894B2 over the INVOKAMET® formulations at issue. Janssen avoids the cost and uncertainty of full Hatch-Waxman trial proceedings. The court’s retained jurisdiction means any breach by Macleods of agreed entry restrictions can be addressed swiftly. The public record does not specify whether royalties or a licence were also agreed.
Exclusivity likely preserved near-termMacleods accepts court-binding terms — future launch date likely negotiated
By consenting to judgment, Macleods avoided the risk of an adverse trial ruling that could have blocked market entry entirely or awarded Janssen damages. Consent judgments in ANDA cases typically include a negotiated authorised entry date, allowing the generic manufacturer to plan commercial launch with legal certainty. However, the precise entry date and any licensing terms are not visible in the public case record. Macleods’ exposure to enforcement action for any breach is now court-backed.
Entry terms agreed, details not publicINVOKAMET® patent barrier reinforced — sector watches for entry date signals
US11576894B2 continues to stand as an enforceable barrier against Macleods’ specific ANDA for canagliflozin/metformin combination tablets. Other generic applicants with pending ANDAs for the same product will not be directly bound by this consent order, but may infer the patent’s near-term enforceability. The resolution also signals that Janssen is actively defending the INVOKAMET® franchise and willing to pursue and enforce ANDA litigation across multiple generic challengers in the D.N.J. forum.
Active patent enforcement signalFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Janssen Pharmaceuticals, Inc. | Company | Pharmaceutical company — branded INVOKAMET® holder and asserting party on US11576894B2Search in Eureka ↗ |
| Co-Plaintiff | Janssen Pharmaceutica, N.V. | Individual | Search in Eureka ↗ |
| Defendant | Macleods Pharmaceuticals | Individual | Generic pharmaceutical manufacturer and U.S. subsidiary seeking ANDA approval for canagliflozin/metformin tabletsSearch in Eureka ↗ |
| Co-Defendant | Macleods Pharma USA, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Keith J. Miller | Attorney | Counsel for Janssen Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Robinson Miller LLC | Law Firm | Representing Janssen Pharmaceuticals, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The consent judgment directs the Clerk to close the matter while expressly reserving the court’s jurisdiction over both Janssen and Macleods for enforcement — a structurally significant provision signalling that the order imposes ongoing obligations on at least one party. In Hatch-Waxman cases, this formulation is consistent with agreed market-entry restrictions or an authorised launch date. The verdict does not specify royalties, invalidity admissions, or infringement findings on the merits, meaning no public precedent on patent scope was established by this proceeding.
US11576894B2 — Canagliflozin and Metformin Hydrochloride Combination Tablet Formulations
US11576894B2, filed under application number US15/413480, protects formulations of INVOKAMET® — a fixed-dose combination of canagliflozin (an SGLT2 inhibitor) and metformin hydrochloride (a biguanide antihyperglycaemic) in four commercially relevant dosage strengths. The patent addresses the pharmaceutical challenge of combining two mechanistically distinct antidiabetic agents in a single stable tablet, a technically non-trivial formulation problem given the differing physicochemical properties of the two actives.
INVOKAMET® is a commercial cornerstone of Janssen’s diabetes portfolio, and US11576894B2 represents a formulation-layer patent that sits above the active ingredient level — making it particularly relevant to Paragraph IV ANDA challenges. For any generic manufacturer seeking to market canagliflozin/metformin combination tablets in the U.S., this patent is a primary obstacle. Its enforcement via consent judgment in under seven months suggests Janssen views it as a strong, defensible asset and will pursue litigation promptly against ANDA filers.
Should you run an FTO analysis against US11576894B2 before filing an INVOKAMET® ANDA?
Any pharmaceutical company, CDMO, or generic manufacturer developing a fixed-dose combination of canagliflozin and metformin hydrochloride for the U.S. market should treat US11576894B2 as a mandatory FTO checkpoint. The consent judgment in this case confirms Janssen’s active enforcement posture. A pre-ANDA FTO analysis should cover claim-level mapping of proposed tablet formulations against the patent’s composition and method claims across all four commercial dosage strengths.
PatSnap Eureka’s FTO Search Agent can rapidly map the claim landscape of US11576894B2 against your proposed formulation parameters, identify prior art relevant to any invalidity arguments, and flag related continuation or divisional applications that may present parallel risks. Eureka also monitors litigation activity across the INVOKAMET® patent family, alerting your team to new enforcement actions that could affect your ANDA timeline or litigation strategy.
Run a freedom-to-operate analysis on US11576894B2 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA Patent Infringement Cases: SGLT2 & Diabetes Combination Drug Litigation in D.N.J.
These cases involve comparable Hatch-Waxman ANDA infringement actions over SGLT2 inhibitor and diabetes combination drug patents litigated in the District of New Jersey.
What this case signals for the SGLT2/diabetes combination drug IP landscape
Janssen’s swift enforcement and consent judgment outcome reinforces the strength of the INVOKAMET® patent estate against generic ANDA challengers in D.N.J.
D.N.J. remains the dominant forum for ANDA patent enforcement in branded pharma
Janssen’s choice of New Jersey District Court is consistent with Hatch-Waxman litigation norms — D.N.J. hosts a high concentration of pharmaceutical patent cases and judges experienced in ANDA disputes. Companies monitoring the canagliflozin or broader SGLT2 combination-drug space should track D.N.J. dockets for parallel actions against other generic applicants.
Consent judgments signal negotiating leverage — patent strength matters early
Resolution in under seven months, before substantive motions or trial, suggests Macleods assessed the patent’s validity and infringement risk and opted for certainty. For other generics targeting INVOKAMET®, US11576894B2 should be treated as a high-priority FTO hurdle. A robust invalidity or design-around strategy should be in place before filing an ANDA with a Paragraph IV certification against this patent.
Janssen v Macleods — key questions answered
The case was resolved by a Consent Judgment and Order signed by Judge Georgette Castner on October 29, 2024. The court retained jurisdiction over both parties for enforcement purposes and directed the Clerk to close the matter. The specific terms — including any agreed generic entry date — are not publicly disclosed.
The asserted patent is US11576894B2, filed under application number US15/413480. It covers formulations of INVOKAMET® — canagliflozin and metformin hydrochloride fixed-dose combination tablets — in strengths of 50 mg/500 mg, 50 mg/1000 mg, 150 mg/500 mg, and 150 mg/1000 mg.
A consent judgment is a court-entered order agreed to by both parties. It carries judicial enforcement authority, meaning either party can seek court-ordered compliance without filing a new lawsuit. In Hatch-Waxman ANDA cases, consent judgments typically contain agreed generic entry dates or entry restrictions, though specific terms are often confidential and not reflected in the public docket.
The case was filed on April 4, 2024 and closed on October 29, 2024 — a duration of 208 days. This is notably shorter than the typical Hatch-Waxman trial timeline in the District of New Jersey, which often extends one to three years, suggesting the parties reached a negotiated resolution without proceeding to substantive motion practice or trial.
No. A consent judgment binds only the named parties — Janssen, Janssen Pharmaceutica N.V., Macleods Pharmaceuticals, and Macleods Pharma USA, Inc. Other generic applicants with separate ANDAs for canagliflozin/metformin combination tablets are not bound by this order, but should note that Janssen has demonstrated willingness and speed in pursuing and resolving ANDA infringement actions under US11576894B2.
PatSnap Eureka searches patents and litigation data to answer instantly.